Formed through the acquisition of Newmarket, Biotec and Plasmatec laboratories, the company is the leading provider of syphilis tests to national blood supply services throughout Europe and is also a major provider of malaria tests, enabling blood services to maintain high donor numbers. The growing portfolio includes both finished kits and bulk reagents, with two recently launched CMV Kits maintaining the market leading position. The group has continued to grow with the additions of Microgen Bioproducts and Myconostica during 2011.

During 2010, Lab21 has expanded the availability of its market leading blood bank screening range of diagnostic assays, by securing a 510(k) clearance in the US for the Syphilis TPHA PK Assay. This is the first of a number of FDA approvals that will be sought as the division looks to expand its distribution presence in the world’s largest diagnostic market.

Lab21 has a professional approach combined with detailed product and market knowledge in all its business areas. This has enabled the company to become a trusted supplier to customers, large and small, throughout the world with customers including a number of aid agencies and various NGO's.
 
Read more about Lab21 >